| Next-generation ALK inhibitors: is the median the message? | Lancet Respiratory Medicine | 22 hours | save |  |  |  |  |
| Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial | Lancet Respiratory Medicine | 22 hours | save | | | | |
| Primary ciliary dyskinesia in the genomics age | Lancet Respiratory Medicine | 1 day | save | | | | |
| Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database | Lancet Respiratory Medicine | 4 days | save | | | | |
| India launches tuberculosis prevalence survey | Lancet Respiratory Medicine | 5 days | save | | | | |
| 2019 European Respiratory Society International Congress | Lancet Respiratory Medicine | 5 days | save | | | | |
| Breakthrough in the treatment of drug-resistant tuberculosis | Lancet Respiratory Medicine | 5 days | save | | | | |
| Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study | Lancet Respiratory Medicine | 6 days | save | | | | |
| Towards improved delivery of care in the paediatric ICU | Lancet Respiratory Medicine | 6 days | save | | | | |
| Vaping-induced severe respiratory disease outbreak: what went wrong? | Lancet Respiratory Medicine | 6 days | save | | | | |
| Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial | Lancet Respiratory Medicine | 6 days | save | | | | |
| The long-lasting dark shadow of past and present smoking | Lancet Respiratory Medicine | 6 days | save | | | | |
| Is ex-vivo viral eradication possible? | Lancet Respiratory Medicine | 6 days | save | | | | |
| Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group | Lancet Respiratory Medicine | 11 days | save | | | | |
| Secondary re-analysis of the FEAST trial | Lancet Respiratory Medicine | 18 days | save | | | | |
| Harnessing the microbiome for lung health | Lancet Respiratory Medicine | 18 days | save | | | | |
| IASLC 2019 World Conference on Lung Cancer | Lancet Respiratory Medicine | 25 days | save | | | | |
| US Government contemplates a nationwide ban on flavoured e-cigarette products | Lancet Respiratory Medicine | 29 days | save | | | | |
| Michigan bans flavoured e-cigarette products | Lancet Respiratory Medicine | 29 days | save | | | | |
| Idiopathic pulmonary fibrosis: shifting the concept to irreversible pulmonary fibrosis of many entities | Lancet Respiratory Medicine | 31 days | save | | | | |
| Repeat proposal from the FDA for graphic tobacco warnings | Lancet Respiratory Medicine | 35 days | save | | | | |
| E-cigarettes and dual nicotine replacement therapy for smoking cessation | Lancet Respiratory Medicine | 37 days | save | | | | |
| Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial | Lancet Respiratory Medicine | 37 days | save | | | | |
| Lung volume reduction on the NHS | Lancet Respiratory Medicine | 41 days | save | | | | |
| Occupational exposures are important factors in COPD and other lung diseases | Lancet Respiratory Medicine | 41 days | save | | | | |
| To eliminate racial and ethnic disparities in child health care, more needs to be addressed than just social determinants | Lancet Respiratory Medicine | 41 days | save | | | | |
| US state governments investigate suspected vaping-associated severe lung disease | Lancet Respiratory Medicine | 46 days | save | | | | |
| Correction to Lancet Respir Med 2019; published online Aug 16. http://dx.doi.org/S2213-2600(19)30281-4 | Lancet Respiratory Medicine | 56 days | save | | | | |
| Individualising therapy for drug-sensitive tuberculosis | Lancet Respiratory Medicine | 60 days | save | | | | |
| Breathless and dying on Mount Everest | Lancet Respiratory Medicine | 60 days | save | | | | |
| What's BEST for children with non-cystic fibrosis bronchiectasis? | Lancet Respiratory Medicine | 60 days | save | | | | |
| Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial | Lancet Respiratory Medicine | 60 days | save | | | | |
| When is the right time to discuss ECMO? | Lancet Respiratory Medicine | 64 days | save | | | | |
| Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study | Lancet Respiratory Medicine | 64 days | save | | | | |
| Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial | Lancet Respiratory Medicine | 64 days | save | | | | |
| Pulmonary hypertension associated with idiopathic interstitial pneumonia: is effective pharmacotherapy an impossible dream? | Lancet Respiratory Medicine | 64 days | save | | | | |
| Prospects and challenges of a new live tuberculosis vaccine | Lancet Respiratory Medicine | 64 days | save | | | | |
| Insights and challenges in tuberculosis vaccine development | Lancet Respiratory Medicine | 64 days | save | | | | |
| Raising new questions on best care for bronchiectasis | Lancet Respiratory Medicine | 68 days | save | | | | |
| Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis | Lancet Respiratory Medicine | 68 days | save | | | | |
| The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis | Lancet Respiratory Medicine | 68 days | save | | | | |
| Treatment duration of checkpoint inhibitors for NSCLC | Lancet Respiratory Medicine | 70 days | save | | | | |
| Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial | Lancet Respiratory Medicine | 70 days | save | | | | |
| A new frontier in ARDS trials: phenotyping before randomisation | Lancet Respiratory Medicine | 70 days | save | | | | |
| Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study | Lancet Respiratory Medicine | 91 days | save | | | | |
| Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations | Lancet Respiratory Medicine | 91 days | save | | | | |
| Biomarkers and early treatment of idiopathic pulmonary fibrosis | Lancet Respiratory Medicine | 91 days | save | | | | |
| Germline variants invited to lung cancer screening | Lancet Respiratory Medicine | 91 days | save | | | | |
| Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians | Lancet Respiratory Medicine | 92 days | save | | | | |
| Correction to Lancet Respir Med 2019; 7: 402–16 | Lancet Respiratory Medicine | 92 days | save | | | | |
| | 
report | next » |
| |
